Related Experiment Video

Updated: May 17, 2026

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

Mineralocorticoid receptor antagonism confers cardioprotection in heart failure

Michael R Seawell1, Fahed Al Darazi, Victor Farah

  • 1Division of Cardiovascular Diseases, University of Tennessee Health Science Center, 956 Court Ave., Suite A312, Memphis, TN 38163, USA.

Current Heart Failure Reports
|November 2, 2012
PubMed

Insights

Mineralocorticoid receptor antagonists like spironolactone effectively treat congestive heart failure (CHF) by blocking hormones. This review explores how these drugs also impact electrolytes and reduce cardiac risks.

Area of Science:

  • Cardiology
  • Endocrinology
  • Nephrology

Background:

  • Congestive heart failure (CHF) is linked to hormonal imbalances involving the renin-angiotensin-aldosterone and adrenergic systems.
  • Existing treatments target these hormones, with mineralocorticoid receptor antagonists (MRAs) like spironolactone showing efficacy.
  • The precise mechanisms behind the cardioprotective effects of MRAs are not fully understood.

Purpose of the Study:

  • To review potential pathophysiologic mechanisms for the salutary responses and cardioprotection offered by MRAs.
  • To focus on the impact of catecholamines and aldosterone on cation dyshomeostasis in CHF.
  • To elucidate the link between hormonal dysregulation and adverse cardiac events.

Main Methods:

  • Review of controlled clinical trials and existing literature on CHF pharmacotherapy.
  • Analysis of the role of aldosterone and catecholamines in electrolyte balance.
  • Examination of the consequences of cation dyshomeostasis on cardiac function and structure.

Main Results:

  • Aldosterone and catecholamines significantly affect monovalent and divalent cation balance.
  • Dyshomeostasis leads to hypokalemia, hypomagnesemia, hypocalcemia, and hypozincemia.
  • These electrolyte imbalances contribute to delayed myocardial repolarization, arrhythmias, and cardiomyocyte necrosis.

Conclusions:

  • MRAs offer cardioprotection beyond simply blocking aldosterone.
  • Understanding cation dyshomeostasis provides new insights into MRA mechanisms.
  • Targeting electrolyte imbalances may enhance CHF management and reduce cardiac complications.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...